| Description | Cobolimab (TSR-022) is a potent monoclonal antibody to TIM-3. Cobolimab induces internalization of TIM-3 with an IC50 value of 0.4464 nM. Cobolimab has antitumor activity and can be used to study advanced/metastatic melanoma and advanced hepatocellular carcinoma. |
| In vitro | Cobolimab（0.0001-10 nM；3天）在预先激活的T细胞中促进TIM-3的剂量依赖性内吞作用，IC50值为0.4464 nM[4]。Cobolimab（20 µg/mL；24小时）通过抑制TIM-3显著增加CD8+ T细胞的含量[3]。 |
| Target activity | TIM3:0.4464 nM |
| Synonyms | TSR-022, GSK4069889 |
| molecular weight | N/A |
| CAS | 2022215-65-0 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. 2. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. 3. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447. 4. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. |